Background #
Vasospastic angina, also known as Prinzmetal angina or variant angina, is a clinical condition characterized by transient myocardial ischemia due to episodic coronary artery vasospasm. Unlike stable angina, it typically occurs at rest and is often not triggered by exertion. Symptoms characteristically occur in cyclical patterns, often during the night or early morning hours (between midnight and 8 AM), reflecting increased parasympathetic tone and decreased endogenous nitric oxide production during these hours.[1,2]
First described by Myron Prinzmetal in 1959, this condition represents a unique form of myocardial ischemia that can occur even in the absence of significant atherosclerotic coronary artery disease.[1]
Classification/Types
Pure Vasospastic Angina[1,2]
- No evidence of obstructive coronary artery disease (CAD) on angiography
- Coronary vasospasm occurs in angiographically normal or near-normal coronary arteries
- Represents approximately 40-60% of cases
Mixed Angina [1,2]
- Vasospasm superimposed on fixed coronary stenosis
- Occurs at sites of atherosclerotic plaques or adjacent segments
- May be more difficult to manage
- Represents approximately 40-60% of cases
Microvascular Vasospastic Angina [2]
- Spasm of coronary microvasculature rather than epicardial vessels
- Normal coronary angiography with provocative testing
- Represents a subset of patients with angina and non-obstructive coronary arteries (ANOCA)
Epidemiology
Prevalence
- More common in Japan and East Asian populations (prevalence 40-50% of angina patients in Japan vs. <10% in Western countries) [1,2]
- Accounts for approximately 2-10% of all angina cases in Western populations
- Underdiagnosed in clinical practice due to circadian nature of symptoms
Demographics
- Age: Typically affects younger patients (average age 40-50 years), though can occur at any age [1]
- Sex: More common in women under 50 years in Western populations; male predominance in Japanese studies [1,2]
- Higher prevalence in East Asian populations (genetic and environmental factors)
- Increased incidence in smokers (smoking is the strongest modifiable risk factor) [1,2]
Associated Conditions
- Often associated with other vasospastic disorders: [1,2]
- Raynaud’s phenomenon
- Migraine headaches
- Aspirin-induced asthma
- Allergic disorders
Pathophysiology
Vasospastic angina results from transient, abrupt, marked reduction in coronary artery diameter due to smooth muscle contraction, leading to myocardial ischemia. [1,2]
Mechanisms of Coronary Vasospasm [1,2,3]
1. Endothelial Dysfunction
- Reduced nitric oxide (NO) bioavailability
- Impaired endothelium-dependent vasodilation
- Increased production of endothelin-1 (potent vasoconstrictor)
- Oxidative stress and inflammation
2. Vascular Smooth Muscle Hyperreactivity
- Enhanced calcium sensitivity of smooth muscle cells
- Upregulation of Rho-kinase (ROCK) pathway → increased smooth muscle contraction
- Genetic polymorphisms affecting vascular tone regulation
3. Autonomic Nervous System Imbalance
- Increased parasympathetic tone (explains nocturnal predominance)
- Enhanced alpha-adrenergic receptor sensitivity
- Reduced beta-adrenergic activity
4. Inflammation and Oxidative Stress
- Low-grade vascular inflammation
- Increased reactive oxygen species (ROS)
- Mast cell activation and histamine release
5. Magnesium Deficiency
- Hypomagnesemia can precipitate coronary vasospasm
- Magnesium is a natural calcium channel blocker
Ischemic Cascade
- Coronary vasospasm → severe reduction in coronary blood flow (>70-90% diameter reduction)
- Transmural ischemia (if severe) → ST-segment elevation on ECG
- Myocardial oxygen supply-demand mismatch
- Anginal chest pain
- If prolonged → myocardial injury (troponin elevation) or infarction
Etiology #
Primary Triggers [1,2]
Most Significant:
- Smoking (active or passive): Strongest and most consistent risk factor; promotes endothelial dysfunction and oxidative stress
- Cocaine or methamphetamine use: Potent vasoconstrictors via alpha-adrenergic stimulation
- Marijuana/cannabis use: Emerging evidence suggests association with coronary vasospasm
Other Triggers:
- Emotional stress or hyperventilation: Catecholamine release, respiratory alkalosis
- Cold exposure: Sympathetic activation
- Alcohol (especially withdrawal): Paradoxical vasoconstriction during withdrawal
- Medications:
- Triptans (sumatriptan, rizatriptan) – 5-HT receptor agonists
- Ergot alkaloids (ergotamine, methylergotamine)
- Beta-blockers (non-selective) – may worsen vasospasm by unopposed alpha-adrenergic activity
- Ephedrine, pseudoephedrine
- Fluorouracil (chemotherapy)
- Some immunotherapy agents (immune checkpoint inhibitors)
Predisposing Factors [1,2]
- Genetic susceptibility: Polymorphisms in endothelial nitric oxide synthase (eNOS), Rho-kinase genes
- Autoimmune conditions: Systemic lupus erythematosus, rheumatoid arthritis
- Thyroid disorders: Hypothyroidism, hyperthyroidism
- Electrolyte abnormalities: Hypomagnesemia, hypokalemia
- Insulin resistance and metabolic syndrome
Clinical Presentation #
History (Symptoms) [1,2]
Classic Presentation:
- Chest pain at rest, predominantly occurring at night or early morning (midnight to 8 AM)
- Not provoked by exertion (distinguishes from stable angina)
- Pain characteristics:
- Severe, squeezing, or pressure-like
- Substernal location
- May radiate to jaw, neck, left arm, or back
- Duration: 5-15 minutes (typically shorter than ACS)
- Rapidly relieved by nitroglycerin (within 1-5 minutes)
- Cyclical or clustered episodes: May have multiple episodes over hours to days, then remission for weeks to months
Associated Symptoms:
- Dyspnea
- Diaphoresis
- Nausea
- Palpitations (due to arrhythmias during spasm)
- Syncope or near-syncope (especially if associated with arrhythmias)
Atypical Presentations:
- Silent ischemia: ST-segment changes on Holter monitoring without symptoms
- Sudden cardiac death: Ventricular arrhythmias (VT/VF) as first presentation (rare but serious)
- Out-of-hospital cardiac arrest survivors: Vasospastic angina should be considered
Physical Examination
General Appearance
- Often completely normal between episodes
- During episode: May appear anxious, pale, diaphoretic
Vital Signs During Episode
- Blood pressure: May show transient hypertension (pain-related) or hypotension (if severe ischemia or arrhythmia)
- Heart rate: Tachycardia, bradycardia (especially with inferior territory vasospasm), or arrhythmias
- Oxygen saturation: Usually normal unless severe ischemia or pulmonary edema
Focused Physical Examination
Cardiovascular:
- Usually normal between episodes
- During episode:
- Transient S4 gallop (atrial kick against stiff ventricle)
- Transient S3 gallop (if severe ischemia with LV dysfunction)
- Transient mitral regurgitation murmur (papillary muscle ischemia)
- Irregular rhythm if arrhythmias present
Pulmonary:
- Generally clear unless coexisting pulmonary condition
- Bibasilar crackles if flash pulmonary edema (rare, indicates severe ischemia)
Neurological:
- Rule out cocaine or stimulant intoxication if suspected (agitation, dilated pupils, hypertension)
- Assess for signs of stroke if patient had prolonged arrhythmia
Skin:
- Pallor, diaphoresis during episodes
- Nicotine staining on fingers (smoking history)
- Signs of Raynaud’s phenomenon: Color changes in fingers/toes with cold exposure
Peripheral Vascular:
- Check for Raynaud’s phenomenon (associated vasospastic disorder)
Differential Diagnosis #
Cardiac Causes
- Acute coronary syndrome (ACS): Unstable angina, NSTEMI, STEMI – Most critical to differentiate
- Stable angina: Typically exertional; not common at rest
- Pericarditis: Sharp, pleuritic pain; positional relief; pericardial friction rub
- Aortic dissection: Tearing/ripping pain radiating to back; pulse deficits
- Takotsubo cardiomyopathy: Stress-induced; apical ballooning on echo
- Myocarditis: Recent viral illness; elevated troponin; diffuse ST changes
Non-Cardiac Causes
- Esophageal spasm: May mimic cardiac pain and respond to nitrates (confounding)
- Gastroesophageal reflux disease (GERD): Burning sensation; worse after meals
- Pulmonary embolism: Sudden dyspnea; pleuritic pain; hypoxia
- Panic attacks/anxiety disorders: Hyperventilation; sense of doom; normal ECG
- Costochondritis: Reproducible chest wall tenderness
Drug-Induced
- Cocaine-induced chest pain: Recent use; sympathomimetic signs
- Amphetamine/methamphetamine: Similar presentation to cocaine
- Marijuana/cannabis-associated vasospasm: Emerging recognition
Diagnostic Testing #
Initial Tests
12-Lead Electrocardiogram (ECG) [1,2]
During Episode (Diagnostic):
- Transient ST-segment elevation (≥1 mm in ≥2 contiguous leads) – Hallmark finding
- ST elevation typically resolves within minutes after nitroglycerin or spontaneously
- May show:
- ST-segment depression (reciprocal changes or subendocardial ischemia)
- T-wave peaking or inversion
- QT prolongation
- Ventricular arrhythmias: PVCs, VT, or VF (serious complication)
- AV block or bradyarrhythmias (especially with right coronary artery spasm)
Between Episodes:
- Often completely normal
- May show non-specific ST-T wave changes
ECG Distribution:
- ST elevation location indicates artery in spasm:
- V1-V4: Left anterior descending (LAD)
- II, III, aVF: Right coronary artery (RCA)
- I, aVL, V5-V6: Left circumflex (LCx)
Cardiac Biomarkers [1,2]
- Troponin I/T and CK-MB: Usually NORMAL (brief, reversible ischemia)
- May be elevated if:
- Prolonged vasospasm (>20 minutes) causing myocardial injury
- Recurrent episodes
- Acute myocardial infarction secondary to severe vasospasm
- If elevated → indicates myocardial necrosis; differentiate from primary ACS
Ambulatory Monitoring [1,2]
Holter Monitoring (24-48 Hours)
- May capture spontaneous ST-segment elevations during nocturnal/early morning hours
- Useful for documenting silent ischemia
- Correlate ECG changes with patient symptoms
- May detect ventricular arrhythmias
Event Monitor or Mobile Cardiac Telemetry
- For patients with infrequent symptoms
- Patient-activated or auto-triggered by arrhythmias
Exercise Stress Testing [1,2]
- Typically NORMAL (vasospastic angina occurs at rest, not with exertion)
- NOT useful for diagnosis
- May be useful to exclude obstructive CAD as cause of symptoms
Non-Invasive Imaging
Echocardiography
- Usually normal between episodes
- During episode: May show transient regional wall motion abnormalities
- Assess for structural heart disease (valvular disease, cardiomyopathy)
Coronary CT Angiography (CCTA)
- Limited role in diagnosis of vasospastic angina (evaluates anatomy, not function)
- May help exclude significant obstructive CAD
- May show coronary calcium burden
Invasive Testing
Coronary Angiography with Provocative Testing [1,2,4]
Gold Standard for Diagnosis
Indications:
- High clinical suspicion based on history and ECG findings
- Rule out obstructive CAD
- Confirm diagnosis with provocative testing
Baseline Angiography:
- May show:
- Normal coronary arteries (pure vasospastic angina)
- Non-obstructive CAD (<50% stenosis)
- Obstructive CAD with superimposed vasospasm (mixed angina)
Provocative Testing (Spasm Provocation Test): [1,2,4]
Purpose: Induce coronary vasospasm under controlled conditions to confirm diagnosis
Agents Used:
- Acetylcholine (ACh):
- Most commonly used in Japan and Europe
- Administered via intracoronary injection in incremental doses (20-200 μg)
- Positive test: ≥90% diameter reduction with reproduction of chest pain and/or ischemic ECG changes
- Sensitivity: 90%; Specificity: 99%
- Ergonovine (Ergometrine):
- Used in United States and some European centers
- Intravenous administration in incremental doses (up to 0.4 mg total)
- Positive test: ≥70-90% diameter reduction with symptoms/ECG changes
- Sensitivity: 60-80%; Specificity: 95%
Safety: Performed in catheterization laboratory with immediate access to:
- Intracoronary nitroglycerin (reverses spasm rapidly)
- Defibrillator (for arrhythmias)
- Temporary pacemaker (for bradyarrhythmias)
Contraindications to Provocative Testing:
- Severe left main stenosis
- Severe multi-vessel obstructive CAD
- Severe LV dysfunction (EF <30%)
- Uncontrolled hypertension
- Severe aortic stenosis
- Pregnancy
Complications: Rare but include severe vasospasm, sustained arrhythmias, MI (risk <0.1%)
Additional Tests
- Complete Blood Count (CBC): Rule out anemia
- Comprehensive Metabolic Panel (CMP): Renal function, electrolytes
- Lipid panel: Assess cardiovascular risk
- Thyroid-Stimulating Hormone (TSH): Rule out thyroid disorders
- Magnesium level: Hypomagnesemia can precipitate vasospasm
- Toxicology screen: If substance abuse (cocaine, amphetamines) suspected
- High-sensitivity C-reactive protein (hsCRP): Assess inflammatory state (optional)
Treatment #
The management of vasospastic angina is based on 2013 ESC Guidelines on Myocardial Revascularization, 2019 ESC Guidelines on Chronic Coronary Syndromes, and recent expert consensus documents from the Coronary Vasomotion Disorders International Study Group (COVADIS).[1,2,4,5]
A. Acute Management (During Episode)[1,2]
Immediate Interventions:
- Sublingual Nitroglycerin (NTG) 0.4 mg:
- First-line therapy
- Repeat every 5 minutes (up to 3 doses)
- Provides rapid symptom relief (within 1-5 minutes)
- If pain persists after 3 doses → seek emergency care (rule out ACS)
- Oxygen Therapy:
- Only if SpO₂ <90%
- NOT routinely recommended if normoxic
- Cardiac Monitoring:
- Continuous ECG monitoring during prolonged episodes
- Monitor for arrhythmias (VT, VF, AV block)
- Have defibrillator available
- Intravenous Nitroglycerin:
- For refractory or severe episodes
- Starting dose: 10-20 μg/min; titrate to effect
If in Catheterization Laboratory:
- Intracoronary nitroglycerin: 100-300 μg bolus – reverses spasm within seconds
B. Long-Term Medical Management[1,2,4,5]
The goal is to prevent recurrent episodes and reduce risk of life-threatening arrhythmias or myocardial infarction.
1. First-Line Pharmacologic Therapy
Calcium Channel Blockers (CCBs) – Cornerstone of Therapy (Class I Recommendation) [1,2,4,5]
Mechanism: Block L-type calcium channels → prevent smooth muscle contraction → coronary vasodilation
Preferred Agents:
- Diltiazem (long-acting): 180-360 mg once daily
- Non-dihydropyridine; rate-limiting properties
- Effective in both epicardial and microvascular spasm
- Amlodipine: 5-10 mg once daily
- Long-acting dihydropyridine
- Potent vasodilator; no negative inotropic effect
- Preferred if bradycardia or AV block present
- Nifedipine (long-acting): 30-90 mg once daily
- Dihydropyridine; potent coronary vasodilator
- Avoid short-acting formulation (causes reflex tachycardia)
- Verapamil (long-acting): 120-480 mg once daily
- Non-dihydropyridine; rate-limiting properties
- Alternative to diltiazem
Combination Therapy:
- Often requires two CCBs from different classes (e.g., amlodipine + diltiazem) for adequate control [1,2,4]
- Combination more effective than monotherapy (reduces episodes by 60-90% vs. 40-60%)
- Monitor for hypotension and bradycardia with combination therapy
Long-Acting Nitrates (Class I Recommendation) [1,2,4,5]
Mechanism: NO donors → vasodilation
Agents:
- Isosorbide mononitrate (extended-release): 30-120 mg once daily
- Isosorbide dinitrate: 20-40 mg three times daily
- Transdermal nitroglycerin patches: 0.4-0.8 mg/hr (remove for 10-12 hours nightly to prevent tolerance)
Important:
- Ensure 8-12 hour nitrate-free interval to prevent tolerance
- Often used in combination with CCBs
- Nitrates alone may be insufficient; CCBs more effective
Short-Acting Nitrates (Sublingual NTG):
- All patients should carry sublingual nitroglycerin for breakthrough episodes
2. Adjunctive Therapies
Magnesium Supplementation (Class IIa Recommendation) [2,6]
- Indication: Documented hypomagnesemia or refractory symptoms despite CCBs and nitrates
- Dose: Magnesium oxide 400-800 mg daily or magnesium sulfate IV during acute episodes
- Mechanism: Natural calcium channel blocker; stabilizes smooth muscle
Statins (Class IIa Recommendation) [1,2,5]
- Not primarily for lipid lowering in vasospastic angina
- Pleiotropic effects: Improve endothelial function, reduce oxidative stress, anti-inflammatory
- Preferred agents:
- Fluvastatin: 40-80 mg daily (shown to reduce vasospasm in Japanese studies)
- Atorvastatin: 10-40 mg daily
- Evidence: Reduce frequency of anginal episodes in some studies
Alpha-Adrenergic Blockers (Limited Evidence) [1,2]
- Terazosin, Doxazosin: May be considered in refractory cases
- Mechanism: Block alpha-adrenergic receptors → reduce vasospasm triggered by sympathetic activity
- Limited clinical data
Cilostazol (Class IIb Recommendation) [2]
- Mechanism: Phosphodiesterase-3 inhibitor; antiplatelet and vasodilatory effects
- Dose: 100 mg twice daily
- May be considered in select cases
3. Medications to AVOID (Critical) [1,2,4,5]
Non-Selective Beta-Blockers (Class III – Harm):
- Propranolol, nadolol, carvedilol (non-selective) – CONTRAINDICATED
- Mechanism of harm: Block beta-2 receptors → unopposed alpha-adrenergic vasoconstriction → worsen vasospasm
- Can precipitate severe, refractory vasospasm
Selective Beta-1 Blockers (Use with Caution):
- Metoprolol, atenolol, bisoprolol – Generally avoided unless absolutely necessary
- May be used cautiously if required for other indications (e.g., post-MI, HFrEF) with close monitoring
Other Medications to Avoid:
- Triptans (sumatriptan, rizatriptan) – potent vasoconstrictors
- Ergot alkaloids (ergotamine, methylergotamine)
- Sympathomimetics (pseudoephedrine, ephedrine, cocaine, amphetamines)
- 5-Fluorouracil (chemotherapy) – known to cause vasospasm
Aspirin (Controversial): [1,2,4]
- NOT routinely recommended in pure vasospastic angina without obstructive CAD
- May be beneficial in mixed angina (vasospasm + obstructive CAD)
- Some evidence suggests aspirin may increase vasospasm via thromboxane-prostaglandin imbalance
- Consider in patients with atherosclerotic risk factors
4. Lifestyle Modifications (Class I Recommendation) [1,2,4]
Critical Interventions:
Smoking Cessation:
- Most important intervention (Class I)
- Smoking is the strongest modifiable risk factor
- Cessation reduces recurrent episodes by 70-90%
- Offer pharmacotherapy: varenicline, bupropion, nicotine replacement therapy
- Referral to smoking cessation programs
Avoid Triggers:
- Cold exposure: Dress warmly; avoid sudden temperature changes
- Emotional stress: Stress reduction techniques (meditation, mindfulness, counseling)
- Cocaine, marijuana, stimulants: Complete abstinence
- Alcohol: Limit intake; avoid withdrawal
- Hyperventilation: Breathing exercises
Other Lifestyle Modifications:
- Regular sleep schedule: Maintain consistent sleep-wake cycle
- Avoid overexertion in cold weather
- Warmth during early morning hours (peak time for vasospasm)
5. Interventional Therapies (Very Limited Role) [1,2,4]
Percutaneous Coronary Intervention (PCI):
- NOT beneficial for pure vasospastic angina (no fixed stenosis)
- May be indicated in mixed angina with significant obstructive CAD (>70% stenosis)
- Risk: Stenting may trigger more vasospasm at stent edges
Coronary Artery Bypass Grafting (CABG):
- NOT indicated for pure vasospastic angina
- May be considered in mixed angina with multi-vessel obstructive CAD
Implantable Cardioverter-Defibrillator (ICD): [1,2]
- Consider in patients with:
- Aborted sudden cardiac death due to documented vasospasm-induced VT/VF
- Recurrent life-threatening arrhythmias despite optimal medical therapy
- Multi-vessel spasm with high arrhythmia risk
Prognosis [1,2,4]
Overall Prognosis
- Generally favorable with appropriate treatment
- 5-year survival: 95-97% with medical therapy
- Symptom control: 70-90% of patients achieve good control with CCBs + nitrates
Factors Associated with Poor Prognosis
- Multi-vessel spasm (involves ≥2 coronary arteries)
- Continued smoking
- Underlying obstructive CAD (mixed angina)
- Malignant arrhythmias (VT/VF) at presentation
- Syncope or cardiac arrest as presenting symptom
- Lack of response to medical therapy
Complications
- Acute myocardial infarction: 2-5% per year if untreated
- Sudden cardiac death: Rare (<1%) with optimal therapy
- Ventricular arrhythmias: VT/VF during severe vasospasm
- AV block or severe bradycardia: With RCA spasm
Consults #
Cardiology (All Patients) [1,2]
- Mandatory for diagnostic confirmation with provocative testing
- Long-term management and medication adjustment
- Risk stratification
- Consideration for ICD in high-risk patients (aborted sudden death, recurrent VT/VF)
Addiction Medicine or Substance Abuse Counseling
- If cocaine, methamphetamine, or other substance abuse is identified
- Critical for preventing recurrent episodes
Psychiatry/Psychology
- For significant anxiety or panic disorder (may mimic or coexist with vasospastic angina)
- Stress management and coping strategies
Smoking Cessation Programs
- All active smokers (strongest modifiable risk factor)
Patient Education #
Counseling
Disease Understanding
- Explain nature of vasospastic angina: Temporary coronary artery spasm causing chest pain
- Differentiate from heart attack (though can lead to one if severe/prolonged)
- Emphasize good prognosis with treatment and lifestyle modification
Medication Education
- Carry sublingual nitroglycerin at all times
- Use at first sign of chest pain
- Sit or lie down before taking (prevent falls from hypotension)
- If pain persists after 3 doses (15 minutes) → call 911
- Replace every 6 months; store in original container
- Medication adherence critical:
- CCBs and long-acting nitrates must be taken daily, even if asymptomatic
- Do NOT stop medications abruptly (may precipitate rebound vasospasm)
- Avoid non-selective beta-blockers (worsen vasospasm)
- Report side effects (dizziness, headache, edema) but do not stop medications without consulting physician
Trigger Avoidance [1,2]
- Smoking cessation (most important)
- Avoid cold exposure: Dress warmly; avoid sudden temperature changes
- Avoid emotional stress: Practice relaxation techniques
- Avoid stimulants: Cocaine, methamphetamine, ephedrine, pseudoephedrine
- Avoid certain medications: Triptans (sumatriptan), ergot derivatives
- Moderate alcohol intake: Avoid excessive drinking and withdrawal
Lifestyle Modifications
- Maintain regular sleep schedule
- Avoid overexertion during early morning hours (peak vasospasm time)
- Stay warm during sleep (vasospasm more common in cold environments)
- Manage stress: Meditation, yoga, counseling
When to Seek Emergency Care
- Chest pain lasting >15 minutes despite sublingual nitroglycerin
- New or different chest pain pattern
- Chest pain with syncope, palpitations, or severe dyspnea
- Any loss of consciousness
Screening
Cardiovascular Risk Factor Screening
For all patients with vasospastic angina: [7,8]
- Blood pressure monitoring: Goal <130/80 mmHg
- Lipid panel: Annual screening; manage per standard guidelines
- Diabetes screening: HbA1c or fasting glucose annually
- Weight and BMI: Target BMI 18.5-24.9 kg/m²
USPSTF Recommendations for Cardiovascular Prevention [7,8]
Aspirin for Primary Prevention:
- Ages 40-59 with ≥10% 10-year CVD risk: Individualized decision (Grade C)
- Ages ≥60: Do NOT initiate aspirin for primary prevention (Grade D)
Note: In pure vasospastic angina without obstructive CAD, aspirin is NOT routinely recommended and may worsen vasospasm. In mixed angina with obstructive CAD, aspirin may be beneficial for atherosclerotic disease prevention.
Statin for Primary Prevention:
- Ages 40-75 with ≥1 CVD risk factor AND ≥10% 10-year CVD risk: Prescribe statin (Grade B)
- In vasospastic angina, statins may provide additional benefit through pleiotropic effects (improved endothelial function)
Vaccinations (Recommended for All Patients) [9]
Influenza Vaccine (Annual)
- Reduces cardiovascular events and mortality in patients with cardiovascular disease
- Administer in fall season (September-November)
Pneumococcal Vaccine
- PCV20 (Prevnar 20): Single dose, OR
- PCV15 (Prevnar 15) followed by PPSV23 (Pneumovax 23) ≥1 year later
- Recommended for all adults with cardiovascular disease
COVID-19 Vaccine
- Stay up-to-date with current CDC recommendations
- Reduces severe illness and cardiovascular complications
Tdap (Tetanus-Diphtheria-Pertussis)
- One-time dose if not previously received
- Td or Tdap booster every 10 years
Follow-Up #
Short-Term Follow-Up (First 3 Months) [1,2]
2-4 Weeks After Diagnosis:
- Assess symptom control and response to medications
- Monitor for side effects (hypotension, bradycardia, peripheral edema)
- Reinforce smoking cessation and lifestyle modifications
- Consider Holter monitor if symptoms persist
6-12 Weeks:
- Re-evaluate medication regimen
- Titrate CCB doses if suboptimal control
- Consider adding second CCB or adjunctive therapy if needed
Long-Term Follow-Up [1,2]
Every 3-6 Months (First Year):
- Assess frequency and severity of anginal episodes
- Monitor medication adherence and tolerance
- Screen for triggers (smoking, substance use, medication non-compliance)
- Check blood pressure, heart rate (monitor for excessive bradycardia or hypotension)
- Repeat ECG if new symptoms
Annually (After First Year if Stable):
- Routine follow-up to ensure symptom control
- Cardiovascular risk factor management
- Medication review and adjustment
- Consider repeat Holter monitoring if symptom pattern changes
When to Repeat Testing [1,2]
Holter Monitor or Event Monitor:
- If recurrent symptoms despite therapy
- To document silent ischemia
- To assess arrhythmia burden
Repeat Coronary Angiography with Provocative Testing:
- Generally not necessary if diagnosis confirmed and symptoms controlled
- Consider if:
- Symptoms worsen or become refractory to medical therapy
- Concern for development of obstructive CAD
- Unexplained troponin elevation
Exercise Stress Testing:
- May be useful to exclude development of obstructive CAD if symptom pattern changes
When to Refer Back to Cardiology Urgently [1,2]
- Refractory symptoms despite optimal medical therapy (multi-drug regimen)
- New or worsening symptoms suggesting obstructive CAD
- Syncope or near-syncope (concern for arrhythmias)
- Documented ventricular arrhythmias (VT/VF) → consider ICD
- Troponin elevation suggesting myocardial injury
- Patient non-compliance with critical interventions (e.g., continued smoking, substance abuse)
References #
- Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38(33):2565-2568. https://doi.org/10.1093/eurheartj/ehv351
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. https://doi.org/10.1093/eurheartj/ehz425
- Shimokawa H, Suda A, Takahashi J, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J. 2021;42(44):4592-4600. https://doi.org/10.1093/eurheartj/ehab282
- JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J. 2014;78(11):2779-2801. https://doi.org/10.1253/circj.cj-66-0098
- Ford TJ, Berry C, Crea F, et al. Coronary artery spasm: recent advances. Eur Heart J. 2023;44(12):1023-1035. https://doi.org/10.1093/eurheartj/ehac786
- Teragawa H, Fukuda Y, Matsuda K, et al. Magnesium causes both coronary artery dilation and suppression of coronary artery spasm. Heart Vessels. 2014;29(4):505-513. https://doi.org/10.1007/s00380-013-0399-4
- US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(16):1577-1584. https://doi.org/10.1001/jama.2022.4983
- US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746-753. https://doi.org/10.1001/jama.2022.13044
- Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148(9):e9-e119. https://doi.org/10.1161/CIR.0000000000001168
